Trends in Testosterone Prescription and Public Health Concerns

Joseph Scott Gabrielsen; Bobby B Najari; Joseph P Alukal; Michael L Eisenberg

doi:10.1016/j.ucl.2016.01.010

Trends in Testosterone Prescription and Public Health Concerns

Urol Clin North Am. 2016 May;43(2):261-71. doi: 10.1016/j.ucl.2016.01.010.

Authors

Joseph Scott Gabrielsen¹, Bobby B Najari², Joseph P Alukal³, Michael L Eisenberg⁴

Affiliations

¹ Department of Urology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
² Department of Urology, Weill Cornell Medical College, James Buchanan Brady Foundation, 525 East 68th Street, Starr 9, New York, NY 10065, USA.
³ Departments of Urology and Obstetrics/Gynecology, New York University, 150 East 32nd Street, 2nd Floor, New York, NY 10016, USA.
⁴ Departments of Urology and Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5118, USA. Electronic address: eisenberg@stanford.edu.

PMID: 27132584
DOI: 10.1016/j.ucl.2016.01.010

Abstract

Testosterone supplementation therapy (TST) has become increasingly popular since the turn of the century. Most prescriptions in the U.S. are written by primary care providers, endocrinologists, or urologists. The FDA has requests pharmaceutical companies provide more long term data on efficacy and safety of testosterone products. Results from these studies will help define the appropriate population for TST going forward. It is hoped that these data combined with physician and public education will minimize inappropriate prescribing and allow those likely to benefit from TST to receive it.

Keywords: Hypogonadism; Late-onset hypogonadism; Testosterone replacement therapy; Testosterone supplementation therapy.

Publication types

Review

MeSH terms

Humans
Hypogonadism / drug therapy*
Male
Practice Patterns, Physicians'
Public Health*
Testosterone / therapeutic use*

Substances

Testosterone